Jun 10, 2019
BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process
Jun 05, 2019
Vaccitech Universal Flu Vaccine Passes Phase 2b Clinical Development Milestones
May 30, 2019
BiondVax Announces First Quarter 2019 Financial Results
May 13, 2019
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference
Apr 30, 2019
BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update
Apr 25, 2019
Medicago Awarded "Best New Vaccine Technology/Platform" at the World Vaccine Congress
Apr 22, 2019
European Investment Bank (EIB) Extends Financing Agreement to EUR24 Million Total in Support of BiondVax's Universal Flu Vaccine Ongoing Pivotal Phase 3 Clinical Trial
Apr 15, 2019
BiondVax Universal Flu Vaccine Patent Application Accepted in Australia
Mar 28, 2019
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at IVW2019 Conference
Mar 21, 2019
Last Participant out in USA Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate
Nov 26, 2018
BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate
Nov 19, 2018
BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results
Oct 24, 2018
BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants
Oct 22, 2018
BiondVax Receives EUR8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial
Sep 04, 2018
BiondVax to Present at Influenza 2018 Oxford Conference
Aug 20, 2018
BiondVax Moves to New Universal Flu Vaccine Manufacturing Facility
Aug 14, 2018
BiondVax Receives Second EUR6M Tranche Disbursement From the European Investment Bank (EIB)
Aug 08, 2018
First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
Jun 28, 2018
Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors
Jun 19, 2018
BiondVax Receives Its First EUR6M Tranche Disbursement From the European Investment Bank (EIB)